Miguel M Cabada1, A Clinton White. 1. Infectious Disease Division, Department of Internal Medicine, University of Texas Medical Branch, Galveston, Texas, USA.
Abstract
PURPOSE OF REVIEW: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. RECENT FINDINGS: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. SUMMARY: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.
PURPOSE OF REVIEW: The management of cryptosporidiosis is fraught with controversies. New research on diagnostics and medications has reached the field in recent years. Therefore, familiarity with key features of current management tools is important. We discuss diagnostic and therapeutic aspects of cryptosporidiosis focusing on evidence behind the medications available to date. RECENT FINDINGS: Molecular methods provide a clearer understanding of cryptosporidiosis epidemiology. The major determinants of severity still are host immune status and parasite species. Children and immunosuppressed individuals, especially with HIV/AIDS, are disproportionately affected. Nitazoxanide is an important advance in treatment of HIV negative patients. However, recent research confirms the limited effectiveness of antiparasitic drugs to treat cryptosporidiosis in AIDS. Questions remain about using partially active drugs paromomycin and nitazoxanide for treatment. Potent antiretroviral combinations modify disease epidemiology and are key components of therapy in AIDS. However, it is unclear whether this is due solely to immune reconstitution or due in part to antiparasitic effects of HIV protease inhibitors. Newer candidate drugs are in development. SUMMARY: There is better understanding of the epidemiology of cryptosporidiosis and promising new diagnostic methods. There are significant challenges in terms of control and treatment of cryptosporidiosis among the groups at risk.
Authors: Anoli J Borad; Geneve M Allison; David Wang; Sabeena Ahmed; Mohammad M Karim; Anne V Kane; Joy Moy; Patricia L Hibberd; Sitara Swarna Rao Ajjampur; Gagandeep Kang; Stephen B Calderwood; Edward T Ryan; Elena Naumova; Wasif A Khan; Honorine D Ward Journal: Am J Trop Med Hyg Date: 2012-02 Impact factor: 2.345
Authors: Suresh Kumar Gorla; Nina N McNair; Guangyi Yang; Song Gao; Ming Hu; Venkatakrishna R Jala; Bodduluri Haribabu; Boris Striepen; Gregory D Cuny; Jan R Mead; Lizbeth Hedstrom Journal: Antimicrob Agents Chemother Date: 2013-12-23 Impact factor: 5.191
Authors: Patricia B Pavlinac; Grace C John-Stewart; Jaqueline M Naulikha; Frankline M Onchiri; Donna M Denno; Elizabeth A Odundo; Benson O Singa; Barbra A Richardson; Judd L Walson Journal: AIDS Date: 2014-09-24 Impact factor: 4.177
Authors: Deborah A Schaefer; Dana P Betzer; Kylie D Smith; Zachary G Millman; Hannah C Michalski; Sarah E Menchaca; Jennifer A Zambriski; Kayode K Ojo; Matthew A Hulverson; Samuel L M Arnold; Kasey L Rivas; Rama S R Vidadala; Wenlin Huang; Lynn K Barrett; Dustin J Maly; Erkang Fan; Wesley C Van Voorhis; Michael W Riggs Journal: J Infect Dis Date: 2016-10-17 Impact factor: 5.226
Authors: George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim Journal: Pediatr Infect Dis J Date: 2013-11 Impact factor: 2.129
Authors: Jose Luis Paredes; Hayley Sparks; A Clinton White; Griselle Martinez-Traverso; Theresa Ochoa; Alejandro Castellanos-González Journal: Am J Trop Med Hyg Date: 2017-07-19 Impact factor: 2.345